900 Chesapeake Drive
Redwood City, CA 94063
United States
650 665 9295
https://www.boltbio.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 100
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Mr. William P. Quinn | CEO, CFO, President, Secretary & Director | 610.8k | N/D | 1971 |
Mr. Grant Yonehiro C.F.A., M.B.A. | Chief Operating Officer | 564.65k | N/D | 1964 |
Ms. Sarah Nemec | VP of Finance & Principal Accounting Officer | N/D | N/D | 1976 |
Mr. Wesley Burwell | VP & Head of Human Resources | N/D | N/D | N/D |
Dr. Nathan Ihle Ph.D. | Senior Vice President of Pharmaceutical Operations | N/D | N/D | N/D |
Dr. Dawn Colburn BCOP, Pharm.D. | Senior Vice President of Clinical Development | N/D | N/D | N/D |
Dr. Michael N. Alonso Ph.D. | Senior Vice President of Research | N/D | N/D | N/D |
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
La calificación ISS Governance QuickScore de Bolt Biotherapeutics, Inc. a partir del 1 de octubre de 2024 es 9. Las puntuaciones principales son Auditoría: 9; Junta: 10; Derechos del accionista: 8; Compensación: 8.